Strategic Partnerships Iconovo collaborates with international pharmaceutical companies to develop inhaled medicinal products, presenting opportunities for sales outreach to potential partners seeking proven inhalation platforms and formulation capabilities.

Inhalation Expertise With patented dry powder inhalers and in-house device and formulation development, Iconovo offers a turnkey solution that reduces downstream client risk and accelerates time-to-market, a compelling value prop for pharma looking to outsource device/formulation work.

Recent Leadership Appointment of an interim CEO and active liquidity provider arrangements signal a transition phase and potential for greater investor and partner engagement, presenting a window for strategic BD outreach to secure collaborations and funding discussions.

Awarded Credibility Recognition as Best Inhalation Therapy Company in 2024 enhances market legitimacy and can be leveraged in outreach to prospective clients and licensors seeking credible inhalation technology platforms.

Growth Opportunities Recent partnerships, including with Lonza on spray-dried intranasal formulations and ongoing development of inhalable oxytocin for postpartum hemorrhage, indicate expanding application areas and co-development deals that sales teams can target across biotech and pharma verticals.